Clinical trials: Intravenous Therapy
Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin
Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease
The purpose of this study is to evaluate the efficacy and safety of TA-650 in comparison with a control drug Polyethylene Glycol-treated Human Immunoglobulin (VGIH) in patients with Kawasaki disease refractory to initial therapy…
- Trial name
- NCT01596335
- Testing
- TA-650, Polyethylene Glycol-treated Human Immunoglobulin (VGIH)
- Where
- 8 sites in Japan
- Volunteers
- 31 people
- Sponsor
- Tanabe Pharma Corporation
Glioblastoma Multiforme of Brain, Glioma, Sarcomatous
Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®
This study is the first step in testing the hypothesis that adding Photobac® Photodynamic Therapy to surgical removal of a glioblastoma or gliosarcoma will be both safe and effective.
- Trial name
- NCT05363826
- Testing
- photochemotherapy using 3-(1-Butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester(Photobac®)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Photolitec LLC
Falciparum Malaria, Uncomplicated Malaria
Phase II Dose Ranging Study of Artesunate
The purpose of this study is to compare four regimens using US FDA GMP intravenous artesunate for the treatment of uncomplicated Plasmodium falciparum malaria to identify the most effective treatment regimen as determined by…
- Trial name
- NCT00459615
- Testing
- Artesunate for Injection
- Where
- 2 sites in Kenya, Thailand
- Volunteers
- 120 people
- Sponsor
- U.S. Army Office of the Surgeon General
Secondary Hyperparathyroidism, Chronic Kidney Disease
Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)
The primary objective is to demonstrate that treatment with etelcalcetide (AMG 416) is not inferior to treatment with cinacalcet for lowering serum intact parathyroid hormone (PTH) levels by > 30% from baseline among participants…
- Trial name
- NCT03299244
- Testing
- Etelcalcetide, Cinacalcet
- Where
- 90 sites in China, Hong Kong and 4 more
- Volunteers
- 637 people
- Sponsor
- Amgen
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer
RATIONALE: Giving chemotherapy drugs, such as busulfan and etoposide, and intensity-modulated radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Trial name
- NCT00540995
- Testing
- busulfan, etoposide, intensity-modulated radiation therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Cystic Fibrosis
Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis
Cystic Fibrosis patients attending with infective exacerbations will be enrolled into the study. The trial is a double blinded, randomised trial with patients randomised to 10,14 or 21 days of antibiotic therapy, comprising of…
- Trial name
- NCT01044719
- Testing
- Ceftazidime, Tobramycin, Meropenem
- Where
- United Kingdom
- Volunteers
- 240 people
- Sponsor
- Imperial College London
Liver Disease
Compassionate Use of IV Fish Oil for Parenteral Nutrition (PN) Liver Injury
To establish a process by which critically ill infants with parenteral nutrition-associated liver disease can receive a fish oil-based intravenous lipid emulsion (Omegaven®) for compassionate use when no satisfactory alternative…
- Trial name
- Omegaven (NCT01425567)
- Testing
- Intravenous Lipid Emulsion Comprised of Fish Oil
- Where
- United States
- Sponsor
- The University of Texas Health Science Center at San Antonio
Migraine Headache
Auricular Acupuncture vs SOC in Migraine HA
Patients with migraine headache will be offered the opportunity to participate in this randomized study evaluating auricular acupuncture versus standard treatment for migraine headaches for patients in the pediatric emergency…
- Trial name
- MigAcu (NCT02681211)
- Testing
- Auricular Acupuncture, Ketorolac 0.5mg/kg, max 30mg, Metoclopramide 0.1 mg/kg, max 10mg
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- University of Louisville
Kidney Cancer
Interleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Biological therapies, such as interleukin-2 and interferon, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00416871
- Testing
- aldesleukin, recombinant interferon alfa
- Volunteers
- 220 people
- Sponsor
- Centre Leon Berard
CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC)
SIDEC - (Subcutaneous Immunoglobulin in De-novo CIDP) ia a study designed as a randomized, parallel study with an open-label extension phase.
- Trial name
- SIDEC (NCT04589299)
- Testing
- Immunoglobulin
- Where
- 4 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- University of Aarhus
Leukemia, Lymphocytic, Chronic, B-Cell
Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib
Intravenous BI 836826 in combination with ibrutinib in relapsed/refractory Chronic Lymphocytic Leukemia (CLL) patients who have been pre-treated with at least one prior line of systemic therapy, and who are eligible for treatment…
- Trial name
- NCT02759016
- Testing
- BI 836826, Ibrutinib
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Boehringer Ingelheim
Headache (Migraine)
Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine.
To determine whether a single dose of intravenous lornoxicam is superior to intravenous placebo for the acute treatment of moderate or severe headache associated with a single migraine attack in patients with a history of…
- Trial name
- NCT00293657
- Testing
- Lornoxicam 8 mg, Lornoxicam 16 mg
- Where
- 23 sites in United States
- Volunteers
- 150 people
- Sponsor
- POZEN
Iron Deficiency Anemia
Total Dose Infusion of Ferumoxytol(1020mg) in 15 Minutes for Iron Deficiency Anemia
The aim of the study is to recruit 30 patients who have been referred to Auerach Hematology Oncology Assoc. for the treatment of iron defeciency anemia with iv iron (Ferumoxytol 1020 mg) administered via infusion pump over 15…
- Trial name
- NCT01374919
- Testing
- ferumoxytol
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Auerbach Hematology Oncology Associates P C
Pulmonary Arterial Hypertension
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies
- Trial name
- Aspire (NCT01266265)
- Testing
- inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin
- Where
- 88 sites in United States
- Volunteers
- 1,333 people
- Sponsor
- United Therapeutics
Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis
Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.
Patients diagnosed with Stevens-Johnson syndrome and Toxic Epidermal Necrolysis were confirmed based on the investigators national diagnostic criteria.
- Trial name
- NCT01696500
- Testing
- Intravenous immunoglobulin
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Nihon Pharmaceutical Co., Ltd
Anemia, Iron Deficiency, Delivery Complication
Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia
This trial will be a comparative pragmatic open label feasibility randomized controlled trial of oral daily versus IV iron in anemic postpartum patients.
- Trial name
- IVIRONMAN (NCT05047211)
- Testing
- Ferrous sulfate, Iron dextran
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Myocardial Diseases, Parvovirus B19, Human
Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy
A prospective randomized double-blind placebo-controlled trail to investigate the effect of high doses of IVIg on cardiac functional capacity and virus presence in a subgroup of patients with chronic symptomatic ICM and a high…
- Trial name
- NCT00892112
- Testing
- Intravenous Immunoglobulins, plasma volume expander
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Prothya Biosolutions
Lumbar Disc Degeneration, Surgical Procedure, Unspecified
Evaluation of Topical and Intravenous Tranexamic Acid in Surgical Treatment of Lumbar Degenerative Disease
Evaluation of Topical and Intravenous Tranexamic Acid in Surgical Treatment of Lumbar Degenerative Disease
- Trial name
- NCT02496364
- Testing
- Observational
- Sponsor
- Vinicius Magno da Rocha, MD, MSc
HIV Infected Individuals, Osteopenia
Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals
The goal of this clinical trial is to learn if zolendric acid can prevent the anticipated deterioration of bone mass after antiviral treatment initiation for people that were recently diagnosed with HIV.
- Trial name
- NCT06762730
- Testing
- Zoledronic Acid 5 mg/Bag 100 ml Inj
- Where
- 3 sites in Israel
- Volunteers
- 110 people
- Sponsor
- Hadassah Medical Organization
Immune Thrombocytopenic Purpura
Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)
This trial is designed as a multi-centre, single-dose, exploratory dose-finding, open label trial evaluating the safety and efficacy of Sym001 in 4-9 consecutive cohorts. Subjects will receive a single IV dose of Sym001.
- Trial name
- NCT00718692
- Testing
- Sym001
- Where
- 59 sites in United States, Belgium and 10 more
- Volunteers
- 61 people
- Sponsor
- Symphogen A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.